作者
Denise Haslwanter, M Eugenia Dieterle, Anna Z Wec, Cecilia M O’brien, Mrunal Sakharkar, Catalina Florez, Karen Tong, C Garrett Rappazzo, Gorka Lasso, Olivia Vergnolle, Ariel S Wirchnianski, Robert H Bortz III, Ethan Laudermilch, J Maximilian Fels, Amanda Mengotto, Ryan J Malonis, George I Georgiev, Jose A Quiroz, Daniel Wrapp, Nianshuang Wang, Kathryn E Dye, Jason Barnhill, John M Dye, Jason S McLellan, Johanna P Daily, Jonathan R Lai, Andrew S Herbert, Laura M Walker, Kartik Chandran, Rohit K Jangra
发表日期
2021/10/5
期刊
Mbio
卷号
12
期号
5
页码范围
e02473-21
出版商
American Society for Microbiology
简介
Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain (RBD) of the spike (S) protein. Variants of concern (VOC) carrying mutations in the RBD or other regions of S reduce the effectiveness of many nAbs and vaccines by evading neutralization. Therefore, therapies that are less susceptible to resistance are urgently needed. Here, we characterized the memory B-cell repertoire of COVID-19 convalescent donors and analyzed their RBD and non-RBD nAbs. We found that many of the non-RBD-targeting nAbs were specific to the N-terminal domain (NTD). Using neutralization assays with authentic SARS-CoV-2 and a recombinant vesicular stomatitis virus carrying SARS-CoV-2 S protein (rVSV-SARS2), we defined a panel of potent RBD and NTD nAbs. Next, we used a combination of …
学术搜索中的文章
D Haslwanter, ME Dieterle, AZ Wec, CM O'brien… - Mbio, 2021